Standing Orders for Administering Influenza Vaccine to Adults

Purpose
To reduce morbidity and mortality from influenza by vaccinating all adults who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

Policy
Standing orders enable eligible nurses and other health care professionals to assess the need for vaccination and to vaccinate adults accordance with the criteria outlined below.

Procedure
1. Assess Adults for Need of Vaccination Against Influenza.
   - All adults are recommended to receive influenza vaccination each year.
   - People who do not recall whether they received influenza vaccine this year should be vaccinated.

2. Screen for Contraindications and Precautions.
   Contraindications for use of all influenza vaccines:
   Do not give influenza vaccine to a person who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components. For a list of vaccine components, refer to the manufacturer's package insert (www.immunize.org/packageinserts) or go to www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf.

   Contraindications only for use of live attenuated influenza vaccine (LAIV, FluMist, nasal spray):
   Do not give live attenuated influenza vaccine (LAIV; nasal spray) to a person who:
   - has a history of either an anaphylactic or non-anaphylactic allergy to eggs
   - is pregnant
   - has immunosuppression (including that caused by medications or HIV)
   - is age 50 years or older
   - received influenza antivirals (e.g., amantadine, rimantadine, zanamivir, or oseltamivir) within the previous 48 hours or will possibly receive them within 14 days after vaccination
   - provides care for a severely immunosuppressed person who requires a protective environment

   Precautions for use of all influenza vaccines:
   - Moderate or severe acute illness with or without fever
   - History of Guillain-Barre Syndrome within 6 weeks of a previous influenza vaccination

   Precautions for use of LAIV only:
   - Asthma
   - Other chronic medical conditions (e.g., other chronic lung diseases, chronic cardiovascular disease [excluding isolated hypertension], diabetes, chronic renal or hepatic disease, hematologic disease, neurologic disease, and metabolic disorders)

   NOTE REGARDING PATIENTS WITH HIVES AFTER EATING EGGS: An egg-free recombinant hemagglutinin influenza vaccine (RIV3) may be used for people age 18 years and older with egg allergy of any severity. For people who experience onset of hives only (and not a more serious reaction) after ingesting eggs, health care providers should administer inactivated influenza vaccine (IIV) and observe the patient for at least 30 minutes after receipt of the vaccine for signs of a reaction.

With permission, this standing order has been adapted for use by SFMC Internal Medicine Clinic from a vaccine standing order template produced by Immunization Action Coalition. Technical content has been reviewed by the Centers for Disease Control and Prevention.
3. Provide Vaccine Information Statements

Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Provide non-English speaking patients with a copy of the VIS in their native language, if one is available and desired; these can be found at www.immunize.org/vis. (For information about how to document that the VIS was given, see section 6 titled "Document Vaccination."

4. Prepare to Administer Vaccine

For vaccine that is to be administered intramuscularly, choose the needle gauge, needle length, and injection site according to the following chart:

<table>
<thead>
<tr>
<th>CENTER AND WEIGHT OF PATIENT</th>
<th>NEEDLE GAUGE</th>
<th>NEEDLE LENGTH</th>
<th>INJECTION SITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female or male less than 130 lbs</td>
<td>22-25</td>
<td>5/8*-1&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female or male 130-152 lbs</td>
<td>22-25</td>
<td>1&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 153-200 lbs</td>
<td>22-25</td>
<td>1-1½&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 153-260 lbs</td>
<td>22-25</td>
<td>1-1½&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 200+ lbs</td>
<td>22-25</td>
<td>1½&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 260+ lbs</td>
<td>22-25</td>
<td>1½&quot;</td>
<td>Deltoid muscle of arm</td>
</tr>
</tbody>
</table>

* A 5/8" needle may be used in patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle only if the skin is stretched tight, the subcutaneous tissue is not bunched, and the injection is made at a 90-degree angle to the skin.

For vaccine that is to be administered intranasally or intradermally, prepare the vaccine according to directions in the package insert.

5. Administer Influenza Vaccine according to the criteria and guidance in the table below:

<table>
<thead>
<tr>
<th>TYPE OF VACCINE</th>
<th>AGE GROUP</th>
<th>DOSE</th>
<th>ROUTE</th>
<th>INSTRUCTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactivated influenza vaccine (IIV)</td>
<td>All ages</td>
<td>0.5 ml</td>
<td>Intramuscular (IM)</td>
<td>Administer vaccine in deltoid muscle.</td>
</tr>
<tr>
<td>IIV-intradermal</td>
<td>18 through  64 years</td>
<td>0.1 ml</td>
<td>Intradermal (ID)</td>
<td>Insert needle of the microinjection system at a 90 degree angle in the deltoid area.</td>
</tr>
<tr>
<td>IIV-high dose</td>
<td>65 years and older</td>
<td>0.5 ml</td>
<td>Intramuscular (IM)</td>
<td>Administer vaccine in deltoid muscle.</td>
</tr>
<tr>
<td>Recombinant influenza vaccine (RIV3)</td>
<td>18 years and older</td>
<td>0.5 ml</td>
<td>Intramuscular (IM)</td>
<td>Administer vaccine in deltoid muscle.</td>
</tr>
<tr>
<td>Intranasal influenza vaccine (IIV)</td>
<td>Healthy, younger than age 50 years</td>
<td>0.2 ml (0.1 ml into each nostril</td>
<td>Intranasal spray (NAS)</td>
<td>Spray half of vaccine into each nostril while the patient is in an upright position.</td>
</tr>
</tbody>
</table>

For complete instructions on how to administer influenza vaccine, see "How to Administer Intramuscular, Intradermal, and Intranasal Influenza Vaccines" at www.immunize.org/catg.d/p2024.pdf.
ST. FRANCIS MEDICAL CENTER VACCINE ADMINISTRATION POLICY
INFLUENZA VACCINE
TRENTON, NJ

6. Document Vaccination

Document each patient's vaccine administration information and follow up in the following places:

Medical record: Document the date the vaccine was administered, the manufacturer and lot number, the vaccination site and route, and the name and title of the person administering the vaccine. You must also document, in the patient's medical record or office log, the publication date of the VIS and the date it was given to the patient. If vaccine was not administered, record the reason(s) for non-receipt of the vaccine (e.g., medical contraindication, patient refusal).

Personal immunization record card: Record the date of vaccination and the name/location of the administering clinic.

Immunization Information System (IIS) or "registry": Report the vaccination to the appropriate state/local IIS, if available.

7. Be Prepared to Manage Medical Emergencies

Be prepared for management of a medical emergency related to the administration of vaccine by having a written emergency medical protocol available, as well as equipment and medications. For Immunization Action Coalition's "Medical Management of Vaccine Reactions in Adults," go to www.immunize.org/catg.d/p3082.pdf. To prevent syncope, vaccinate patients while they are seated or lying down and consider observing them for 15 minutes after receipt of the vaccine.

8. Report All Adverse Events to VAERS

Report all adverse events following the administration of influenza vaccine to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov. Forms are available on the website or by calling (800) 822-7967.

Standing Orders Authorization

This policy and procedure shall remain in effect for all patients of the SFMC Internal Medicine Clinic until rescinded.

Medical Director’s Signature: ___________________________

Date Signed: ________________

Effective Date: ________________